Physician profile
Michael W Mapp
NPI 1235230228
$8,005.17
in general payments reported to CMS, 2019-2025
23 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $147 · 2021: $419 · 2022: $789 · 2023: $3,654 · 2024: $1,101 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282 · Consulting Fee: $2,540 · Travel and Lodging: $287 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,282.45 |
| Consulting Fee | $2,540.00 |
| Travel and Lodging | $286.64 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,853.47 | 2023-2025 | Vabysmo |
| Abbvie INC. | $1,858.71 | 2022-2025 | |
| Alcon Vision LLC | $667.98 | 2020-2025 | Lensx, Clareon, Argos |
| Johnson & Johnson Surgical Vision, INC. | $411.17 | 2021-2025 | Tecnis Simplicity, Tecnis Iol, Whitestar Signature |
| Ocular Therapeutix, INC. | $360.81 | 2021-2025 | Dextenza |
| Bausch & Lomb Americas INC. | $332.08 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Mallinckrodt Hospital Products INC. | $216.34 | 2021-2025 | Acthar |
| Allergan, INC. | $211.92 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $170.62 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $144.16 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $134.86 | 2019-2020 | |
| Harrow Eye, LLC | $111.27 | 2025 | Iheezo, Vevye |
| Beaver-Visitec International, INC. | $89.29 | 2021 | |
| Emd Serono, INC. | $69.88 | 2019 | |
| Sight Sciences, INC. | $69.53 | 2019-2024 | Omni Surgical System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $66.95 | 2020-2025 | Idosetr |
| Dompe US, INC. | $59.24 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $44.38 | 2022-2023 | Tyrvaya |
| Shire North American Group INC | $42.14 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $42.01 | 2024-2025 | Xdemvy |
| Rxsight INC | $18.67 | 2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $17.09 | 2023 | Cequa |
| Biotissue Holdings INC. | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.